Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C5H5N3O
CAS Number:
Molecular Weight:
123.11
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
MDL number:
Beilstein/REAXYS Number:
112306
Product Name
Pyrazinamide, European Pharmacopoeia (EP) Reference Standard
InChI key
IPEHBUMCGVEMRF-UHFFFAOYSA-N
SMILES string
NC(=O)c1cnccn1
InChI
1S/C5H5N3O/c6-5(9)4-3-7-1-2-8-4/h1-3H,(H2,6,9)
grade
pharmaceutical primary standard
API family
pyrazinamide
manufacturer/tradename
EDQM
mp
189-191 °C (lit.)
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
Looking for similar products? Visit Product Comparison Guide
Application
Pyrazinamide EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Other Notes
Sales restrictions may apply.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
A Somoskovi et al.
Respiratory research, 2(3), 164-168 (2001-11-01)
Multidrug-resistant (MDR) strains of Mycobacterium tuberculosis have emerged worldwide. In many countries and regions, these resistant strains constitute a serious threat to the efficacy of tuberculosis control programs. An important element in gaining control of this epidemic is developing an
L Gwaza et al.
Clinical pharmacology and therapeutics, 96(5), 580-588 (2014-07-06)
Approval of generic medicines is based on bioequivalence with the innovator product, but it is not unusual for generics to be interchanged with each other. This study investigated the differences in bioavailability between World Health Organization-prequalified antituberculosis generics by means
D A Mitchison et al.
Tuberculosis (Edinburgh, Scotland), 90(3), 177-181 (2010-04-13)
While we wait for improved new anti-tuberculosis drugs, the main aim for improving current treatment should be to optimize the use of the two current drugs, rifampicin and the pro-drug pyrazinamide, which are responsible to a similar extent for the
Tawanda Gumbo et al.
The Journal of antimicrobial chemotherapy, 69(9), 2420-2425 (2014-05-14)
To identify the pyrazinamide MIC above which standard combination therapy fails. MICs of pyrazinamide were determined for Mycobacterium tuberculosis isolates, cultured from 58 patients in a previous randomized clinical trial in Cape Town, South Africa. The MICs were determined using
X Gonzalo et al.
The Journal of antimicrobial chemotherapy, 69(11), 3001-3005 (2014-06-26)
Pyrazinamide is a key first-line tuberculosis drug. Reliable drug susceptibility testing (DST) data are of clinical importance, but in vitro testing is challenging since the activity of pyrazinamide is pH sensitive. The BACTEC MGIT 960 is considered the principal reference
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service